XR Health acquires Swing Therapeutics for fibromyalgia app
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- XR Health acquired Swing Therapeutics, marking its sixth acquisition in two years as it expands its portfolio of digital treatments.
- Swing Therapeutics developed an FDA-cleared digital treatment for fibromyalgia, which will now be integrated into XR Health’s VR platform.
- XR Health has delivered a million user sessions in 2025 across its platform, which hosts dozens of VR apps targeting mental health, pain, and hot flashes.
- XR Health CEO Eran Orr stated the acquisition terms were not disclosed because the company expects to make more deals in the future.
- XR Health offers FDA-registered but not FDA-cleared bundled VR treatment packages, distinguishing its current regulatory standing from Swing’s cleared product.
Why it matters: XR Health gains an FDA-cleared therapy to strengthen its clinical credibility, while Swing’s treatment reaches a broader platform. The move consolidates XR Health’s position in digital therapeutics, suggesting a shift toward evidence-based offerings in a market where most VR health tools lack clearance.
